Cadaverine Tartrate

Cadaverine Tartrate

SCHEMBL4028282

CCOC(=O)C(C)(C)Oc1cccc(C2CCCNC2)c1.O=C(O)C(O)C(O)C(=O)O

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HTR2A known ✓ P28223 1/20 0.41
BCL9 O00512 13/20 0.44
CTNNB1 P35222 13/20 0.44
PPARA Q07869 3/20 0.43
PPARG P37231 1/20 0.43
FBP1 P09467 1/20 0.41
ABCB11 O95342 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41
PMP22 Q01453 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cadaverine Tartrate SCHEMBL4028278 1.00 BCL9 (0.44) BCL9CTNNB1PPARAPPARGFBP1
SCHEMBL4036258 0.93 PPARA (0.48) BCL9CTNNB1PPARAPPARGFBP1
SCHEMBL5348343 0.93 PPARA (0.48) BCL9CTNNB1PPARAPPARGFBP1
SCHEMBL5361918 0.93 PPARA (0.48) BCL9CTNNB1PPARAPPARGFBP1
Cadaverine Tartrate SCHEMBL4027502 0.89 BCL9 (0.49) BCL9CTNNB1PPARAHTR2A
Cadaverine Tartrate SCHEMBL4031980 0.86 HTR2A (0.41) PPARAFBP1ABCB11CYP1A2CYP3A4
Cadaverine Tartrate SCHEMBL4031976 0.86 HTR2A (0.41) PPARAFBP1ABCB11CYP1A2CYP3A4
SCHEMBL5352899 0.83 BCL9 (0.52) BCL9CTNNB1PPARA
SCHEMBL5349974 0.83 BCL9 (0.52) BCL9CTNNB1PPARA
SCHEMBL4030400 0.83 BCL9 (0.52) BCL9CTNNB1PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567493-B1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS PFIZER PROD INC (US) 2009-03-18 EP disclosed
US-20070191429-A1 PPAR ACTIVATORS PFIZER INC. (US) 2007-08-16 US disclosed
US-7199243-B2 Piperidine compounds useful as PPAR activators PFIZER INC. (US) 2007-04-03 US disclosed
EP-1567493-A1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS Pfizer Products Inc. (US) 2005-08-31 EP disclosed
US-20040157885-A1 PPAR activators PFIZER INC 2004-08-12 US disclosed
WO-2004048334-A1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS PFIZER PRODUCTS INC. (US) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191429-A1 PPAR ACTIVATORS PPARA, PPARG, PPARD HTR2A 1523/4885BCL9 2684/4885CTNNB1 2280/4885
US-20040157885-A1 PPAR activators PPARA, PPARG, PPARD HTR2A 1523/4885BCL9 2684/4885CTNNB1 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.